Patients with an established diagnosis of heart failure (HF) with reduced ejection fraction (HFrEF) are prone to experience episodes of worsening symptoms and signs despite continued therapy, termed "worsening heart failure" (WHF). Despite guideline-directed medical therapy, worsening of chronic heart failure accounts for almost 50% of all hospital admissions for HF, and patients experiencing WHF carry a substantially higher risk of death and hospitalization than patients with "stable" HF. New drugs are emerging as arrows in the quiver for clinicians to address the residual risk of HF hospitalization and cardiovascular deaths in patients with WHF. This question-and-answer-based review will discuss the emerging definition of WHF in light of the recent clinical consensus released by the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), the new therapeutic approaches to treat WHF and then move on to their timing and safety concerns (i.e., renal profile).

New challenges in heart failure with reduced ejection fraction. managing worsening events / Lavalle, Carlo; Di Lullo, Luca; Jabbour, JEAN PIERRE; Palombi, Marta; Trivigno, Sara; Mariani, MARCO VALERIO; Summaria, Francesco; Severino, Paolo; Badagliacca, Roberto; Miraldi, Fabio; Bellasi, Antonio; Vizza, Carmine Dario. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 12:22(2023). [10.3390/jcm12226956]

New challenges in heart failure with reduced ejection fraction. managing worsening events

Carlo Lavalle
Primo
;
Jean Pierre Jabbour;Marta Palombi;Sara Trivigno;Marco Valerio Mariani;Paolo Severino;Roberto Badagliacca;Fabio Miraldi;Carmine Dario Vizza
Ultimo
2023

Abstract

Patients with an established diagnosis of heart failure (HF) with reduced ejection fraction (HFrEF) are prone to experience episodes of worsening symptoms and signs despite continued therapy, termed "worsening heart failure" (WHF). Despite guideline-directed medical therapy, worsening of chronic heart failure accounts for almost 50% of all hospital admissions for HF, and patients experiencing WHF carry a substantially higher risk of death and hospitalization than patients with "stable" HF. New drugs are emerging as arrows in the quiver for clinicians to address the residual risk of HF hospitalization and cardiovascular deaths in patients with WHF. This question-and-answer-based review will discuss the emerging definition of WHF in light of the recent clinical consensus released by the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), the new therapeutic approaches to treat WHF and then move on to their timing and safety concerns (i.e., renal profile).
2023
cardiovascular death; guideline-directed medical therapy; heart failure hospitalization; heart failure with reduced ejection fraction; randomized controlled trial; worsening heart failure.
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
New challenges in heart failure with reduced ejection fraction. managing worsening events / Lavalle, Carlo; Di Lullo, Luca; Jabbour, JEAN PIERRE; Palombi, Marta; Trivigno, Sara; Mariani, MARCO VALERIO; Summaria, Francesco; Severino, Paolo; Badagliacca, Roberto; Miraldi, Fabio; Bellasi, Antonio; Vizza, Carmine Dario. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 12:22(2023). [10.3390/jcm12226956]
File allegati a questo prodotto
File Dimensione Formato  
Lavalle_New-Challenges_2023.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 918.32 kB
Formato Adobe PDF
918.32 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1704202
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact